Integrated CGM and Remote Patient Monitoring (RPM) provides superior health outcomes over 20-year and lifetime horizons compared to CGM alone or SMBG.
The Incremental Cost-Effectiveness Ratio (ICER) for CGM with RPM is approximately $27,400 per QALY, significantly more favorable than CGM alone ($103,700 per QALY).
CGM with RPM remains cost-effective even if real-world clinical efficacy is only 30% of that observed in specialized trials like the 4T Study.
The strategy yields net health care savings by reducing the incidence and costs associated with long-term complications such as ESRD, CVD, and retinopathy.
